InSilico-Con, through Ex-Cello Medico, is revolutionising pharmaceutical development by employing algorithms to create new drug compounds rapidly, bypassing traditional methods. By commercialising their software, they enable major pharma companies to generate candidate treatments with minimal oversight, exemplifying a shift from scientific research to owning software infrastructure for profit.